Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Return on Sales (2020 - 2025)

Historic Return on Sales for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 0.27%.

  • Evoke Pharma's Return on Sales rose 2200.0% to 0.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36%, marking a year-over-year increase of 3500.0%. This contributed to the annual value of 0.52% for FY2024, which is 9800.0% up from last year.
  • Latest data reveals that Evoke Pharma reported Return on Sales of 0.27% as of Q3 2025, which was up 2200.0% from 0.42% recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Return on Sales ranged from a high of 0.27% in Q3 2025 and a low of 29.98% during Q1 2021
  • For the 5-year period, Evoke Pharma's Return on Sales averaged around 3.75%, with its median value being 1.65% (2023).
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -24006900bps in 2021, then skyrocketed by 247800bps in 2022.
  • Evoke Pharma's Return on Sales (Quarter) stood at 4.64% in 2021, then surged by 51bps to 2.26% in 2022, then skyrocketed by 48bps to 1.19% in 2023, then skyrocketed by 70bps to 0.36% in 2024, then increased by 25bps to 0.27% in 2025.
  • Its Return on Sales was 0.27% in Q3 2025, compared to 0.42% in Q2 2025 and 0.42% in Q1 2025.